Once more randomized interventions are conducted, future meta-analyses need to quantify the optimal dose of SB reduction in a population of adults with T2D to improve other cardiometabolic biomarkers (i.e., glucose, insulin, vascular, anthropometric, etc.). The gene discussed is INS; the disease is type 2 diabetes mellitus.